Biochemical and Biophysical Research Communications
Apoptosis induces Bcl-XS and cleaved Bcl-XL in chronic lymphocytic leukaemia
Research highlights
► Bcl-X gene has both pro-survival, Bcl-XL, and pro-apoptotic, Bcl-XS, gene products. ► No well-characterised primary cell systems to test drugs operating through this mechanism exist. ► Bcl-XS and cleaved Bcl-XL were induced in a caspase dependent manner. ► Cleavage of Bcl-XL and production of Bcl-XS both enhance apoptosis. ► Emetine induced apoptosis does not depend on Bcl-XS in primary human leukaemic B-cells.
Introduction
Chronic lymphocytic leukaemia is a common lymphoproliferative disorder in which there is an accumulation of mature lymphocytes in the peripheral blood, lymph nodes and bone marrow. Diverse treatments, using both conventional and novel therapeutic agents, clear circulating leukaemic cells but leukaemic cells continue to survive within the lymph node and bone marrow microenvironments. A variety of model systems [1], [2], [3] have been developed to attempt to reproduce the humoral or cellular aspects of the microenvironment responsible for their improved survival. We are using CD40 ligand (CD154) expressed on the surface of a mouse fibroblast cell line with IL-4 [4], [5], [6] and have found that this causes increased proliferation and resistance to drug-induced and spontaneous apoptosis. Others using the same system have demonstrated that up-regulation of Bcl-2 family pro-survival members Bcl-XL and Bcl2A1 causes improved survival and resistance to apoptosis [7].
Bcl-2 family proteins regulate apoptosis through control of mitochondrial integrity. The Bcl-2 family member, Bcl-X, has two major isoforms Bcl-XL and Bcl-XS, due to alternative splicing [8]. The shorter, Bcl-XS, isoform lacks 63 residues comprising the BH1 and BH2 domains, but has the BH3 and BH4 domains in common with Bcl-XL. Bcl-XL is a pro-survival protein but Bcl-XS is pro-apoptotic [8]. Most work on Bcl-XS expression has been carried out on cell lines.
Utilising cell lines and Bcl-X minigene constructs it has been shown that splicing to the 5′ Bcl-XS site is enforced by a number of RNA binding proteins [9], [10], [11], [12]. More recent work on intracellular signalling pathways has demonstrated that active protein kinase C reduces splicing to Bcl-XS [13].
Ceramides [14] and emetine [15] increase alternative splicing to Bcl-XS in cell lines, suggesting that these agents may form the basis for therapeutically useful strategies. Emetine, a plant alkaloid originally extracted from ipecac root and used as an anti-protozoal agent, increased the ratio of Bcl-XS to Bcl-XL in a C33A cervical cancer cell line [15]. It has also shown potential for use in combination chemotherapy in leukaemias as it seems to increase the efficacy of other drugs such as cisplatin [16]. Ceramide, a cell membrane sphingolipid, was shown to increase Bcl-XS mRNA production at the expense of Bcl-XL [14] in A549 adenocarcinoma cells.
We made the observation that Bcl-XS protein expression is strongly induced during spontaneous apoptosis of CLL cells. Increasing Bcl-XS expression could potentially be exploited therapeutically but it is not known whether Bcl-XS has a primary or secondary role in apoptosis in primary leukaemic B-cells. In this report we analysed the expression of Bcl-X gene products on induction of apoptosis in CLL cells supported on CD154/IL-4.
Section snippets
Cell culture
Blood samples were obtained from patients (Table 1) after informed consent was given. All patients were either untreated or more than 3 months from the end of treatment. Chronic lymphocytic leukaemia (CLL) cells were isolated using density gradient centrifugation. Cells (3 × 106/ml) were cultured in RPMI 1640 medium (Invitrogen, Paisley, UK) supplemented with fetal bovine serum (Invitrogen) and Penicillin/Streptomycin (Invitrogen). Culture conditions were tissue culture plastic alone or co-culture
Bcl-XS protein expression in CLL is induced by spontaneous and drug-induced apoptosis
We investigated Bcl-XL and Bcl-XS expression in primary human leukaemic B-cells. CLL cells survive when cultured on a stromal cell layer (either CD154/IL-4 or NT) but have high rates of spontaneous apoptosis when cultured on tissue culture plastic [5], [17]. By western there is little detectable Bcl-X gene product in freshly isolated CLL cells (Fig. 1A). On culture with CD154/IL-4 Bcl-XL was strongly induced whereas with the fibroblast layer alone (NT) there was a low level of Bcl-XL
Discussion
Signals from the lymph node and bone marrow microenvironments are responsible for the strong survival and proliferation of CLL cells. It is also believed that survival within tissues contributes to the failure of conventional chemotherapy to eliminate leukaemic cells and there is, therefore, interest in developing strategies targeting the lymph node microenvironment and the leukaemic cells existing within this context [1].
We used cell culture conditions to reflect the different
Author contribution
SW designed and carried out experiments. TM carried out experiments. SDW designed experiments and wrote the manuscript.
Conflict of interest
None.
Acknowledgments
ABT-737 was a gift from Abbott Laboratories. This work was supported by a grant from the Kay Kendall Leukaemia Fund to S.D.W.
References (28)
- et al.
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Blood
(2009) - et al.
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1
Blood
(2000) - et al.
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
Blood
(2009) - et al.
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
Blood
(2009) - et al.
Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
Cell
(1993) - et al.
Antagonistic effects of the SRp30c protein and cryptic 5′ splice sites on the alternative splicing of the apoptotic regulator Bcl-X
J. Biol. Chem.
(2008) - et al.
Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-X
J. Biol. Chem.
(2005) - et al.
De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells
J. Biol. Chem.
(2002) - et al.
Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism
Chem. Biol.
(2007) - et al.
Homotypic interactions protect chronic lymphocytic leukaemia cells from spontaneous death in vitro
Leuk. Res.
(2001)